Genomic Medicine Sweden
|Coordinator||Region Skåne - Skånes Universitetssjukhus|
|Funding from Vinnova||SEK 38 773 089|
|Project duration||November 2018 - June 2020|
Purpose and goal
The Genomic Medicine Sweden (GMS) initiative aims to strengthen precision medicine across the country. This will be accomplished through the implementation of large-scale sequencing techniques in Swedish healthcare, resulting in improved healthcare, strengthened Swedish research in the area, and a foundation for innovation and collaboration with industry. With a patient-centered view, we will focus on rare diseases, cancer, pharmacogenetics and infectious diseases. In parallel, efforts will be initiated for common complex diseases for the next phase of GMS.
Expected results and effects
GMS will offer Swedish patients cutting edge diagnostics with possibilities of individually tailored therapy alternatives, where previously none was available. GMS will also offer a unique research resource for Sweden for identifying disease-causing events that could pave the way for new drug development, new treatment options, and enhance collaboration with industry. In summary, GMS provides Sweden with a unique opportunity to take an international forefront position in the field of precision medicine.
Planned approach and implementation
GMS will be implemented as a broad collaborative project between different societal stakeholders including health care providers, universities with medical faculties, Science for Life Laboratory, industry and patient organizations. In order to deliver top tier diagnostics and research, enabling individually adapted therapies and follow-up strategies, regional genomic medicine centers are being formed together with a national informatics infrastructure for data processing, interpretation and storage.